Partnership opportunity

...combining the capability and funding of commercial business with the deepest knowledge of the science.

We are offering to partner with commercial outfits in the biotech industry in an effort to translate discoveries into a product, whether it's a medical treatment or another biotechnology, technical, technological application.

We believe that combining the capability and funding of commercial business with the deepest knowledge of the science can be of significant benefit in enabling potential translation and commercialisation paths for Australian-based research and development.

What we offer

One of our core missions of the Shine-Dalgarno Centre for RNA Innovation is to build partnerships and capabilities to collaborate and innovate around two central themes of interest: RNA THERAPEUTICS and RNA DIAGNOSTICS. The Shine-Dalgarno Centre for RNA Innovation can enrich and support all your RNA research needs through: 

• Understanding the fundamentals of RNA biology 
• Supporting the discovery of new RNA targets 
• Developing new RNA tools  
• Screening of RNA biomarkers and new therapeutics 
• Selecting RNA candidates and optimisation 
• Developing new computational tools 
• Using pre-clinical models for RNA diagnostic and therapeutic validation 
• Designing and implementing your RNA manufacturing needs 

Our competitive edge

At ANU we are working on different parts of RNA technology, targeting the ribosome, or on microRNA, how RNAs are involved in organising DNA, and even computational biology, and this helps set us apart. We are a world-recognised aggregation of people with this focus, with concentrated academic excellence in RNA biology, and in propagating novel uses of RNA science.

We have the established infrastructure to provide screening and testing of RNA molecules or molecules targeting RNA, and early phase clinical trial capability.

Our track record

• Innovated ribosome footprinting to answer long-standing questions regarding the mechanism of mRNA translation; worked with industry to optimise mRNA therapy
• Research on nuclear RNA processing mechanisms led to the development of novel RNase H inhibitors
• Work on ribosome biogenesis revealed new treatment paradigms in cancer with two drugs in clinical trials
• The world’s first protocol to extract retinal extracellular vesicles led to the identification of novel disease-modifying miRNAs as therapeutic targets for AMD
• New CRISPR technologies are being developed for molecular diagnostics and gene therapy
• Computational tools to analyse RNA splicing have found wide adoption in basic biology research as well as in biomedical applications
• World’s first transcriptome-wide map of an RNA modification, a foundational study for the burgeoning field of epitranscriptomics
• Demonstration of histone variants’ role in mRNA splicing

General enquiries

Contact Professor Thomas Preiss